Glycans Instructing Immunity: The Emerging Role of Altered Glycosylation in Clinical Immunology

Frontiers in Pediatrics

Volumn 3, Issue , 2015, Pages

  Lyons, Jonathan J ^a   Milner, Joshua D ^a   Rosenzweig, Sergio D ^a,b  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

allergy; congenital disorders of glycosylation; glycosylation; immunodeficiency; infection susceptibility

Indexed keywords

EID: 85119038728     PISSN: None     EISSN: 22962360     Source Type: Journal    
DOI: 10.3389/fped.2015.00054     Document Type: Review

References (81)

1. Gupta R Brunak S. Prediction of glycosylation across the human proteome and the correlation to protein function. Pac Symp Biocomput (2002). 310–22.10.1142/9789812799623_002911928486
2. Varki A. Essentials of Glycobiology. 2nd ed. (Vol. xxix). Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press (2009). 784 p.
3. Ohtsubo K Marth JD. Glycosylation in cellular mechanisms of health and disease. Cell (2006) 126(5):855–67.10.1016/j.cell.2006.08.01916959566
4. Freeze HH Chong JX Bamshad MJ Ng BG. Solving glycosylation disorders: fundamental approaches reveal complicated pathways. Am J Hum Genet (2014) 94(2):161–75.10.1016/j.ajhg.2013.10.02424507773
5. Marth JD Grewal PK. Mammalian glycosylation in immunity. Nat Rev Immunol (2008) 8(11):874–87.10.1038/nri241718846099
6. van Kooyk Y Rabinovich GA. Protein-glycan interactions in the control of innate and adaptive immune responses. Nat Immunol (2008) 9(6):593–601.10.1038/ni.f.20318490910
7. Helenius A Aebi M. Intracellular functions of N-linked glycans. Science (2001) 291(5512):2364–9.10.1126/science.291.5512.2364
8. Janssens S Pulendran B Lambrecht BN. Emerging functions of the unfolded protein response in immunity. Nat Immunol (2014) 15(10):910–9.10.1038/ni.299125232821
9. Ruggiano A Foresti O Carvalho P. Quality control: ER-associated degradation: protein quality control and beyond. J Cell Biol (2014) 204(6):869–79.10.1083/jcb.20131204224637321
10. Wells L Vosseller K Hart GW. Glycosylation of nucleocytoplasmic proteins: signal transduction and O-GlcNAc. Science (2001) 291(5512):2376–8.10.1126/science.105871411269319
11. Lewis BA Hanover JA. O-GlcNAc and the epigenetic regulation of gene expression. J Biol Chem (2014) 289(50):34440–8.10.1074/jbc.R114.59543925336654
12. Fukuda M Hiraoka N Yeh JC. C-type lectins and sialyl Lewis X oligosaccharides. Versatile roles in cell-cell interaction. J Cell Biol (1999) 147(3):467–70.10.1083/jcb.147.3.467
13. Jaeken J Hennet T Matthijs G Freeze HH. CDG nomenclature: time for a change! Biochim Biophys Acta (2009) 1792(9):825–6.10.1016/j.bbadis.2009.08.005
14. Sperandio M Gleissner CA Ley K. Glycosylation in immune cell trafficking. Immunol Rev (2009) 230(1):97–113.10.1111/j.1600-065X.2009.00795.x
15. Gazit Y Mory A Etzioni A Frydman M Scheuerman O Gershoni-Baruch R et al. Leukocyte adhesion deficiency type II: long-term follow-up and review of the literature. J Clin Immunol (2010) 30(2):308–13.10.1007/s10875-009-9354-020099014
16. Scott DW Patel RP. Endothelial heterogeneity and adhesion molecules N-glycosylation: implications in leukocyte trafficking in inflammation. Glycobiology (2013) 23(6):622–33.10.1093/glycob/cwt01423445551
17. Weber AN Morse MA Gay NJ. Four N-linked glycosylation sites in human toll-like receptor 2 cooperate to direct efficient biosynthesis and secretion. J Biol Chem (2004) 279(33):34589–94.10.1074/jbc.M40383020015173186
18. Partridge EA Le Roy C Di Guglielmo GM Pawling J Cheung P Granovsky M et al. Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science (2004) 306(5693):120–4.10.1126/science.110210915459394
19. Sun J Duffy KE Ranjith-Kumar CT Xiong J Lamb RJ Santos J et al. Structural and functional analyses of the human toll-like receptor 3. Role of glycosylation. J Biol Chem (2006) 281(16):11144–51.10.1074/jbc.M51044220016533755
20. Moncada-Velez M Martinez-Barricarte R Bogunovic D Kong XF Blancas-Galicia L Tirpan C et al. Partial IFN-gammaR2 deficiency is due to protein misfolding and can be rescued by inhibitors of glycosylation. Blood (2013) 122(14):2390–401.10.1182/blood-2013-01-48081423963039
21. Vogt G Chapgier A Yang K Chuzhanova N Feinberg J Fieschi C et al. Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations. Nat Genet (2005) 37(7):692–700.10.1038/ng158115924140
22. Triot A Jarvinen PM Arostegui JI Murugan D Kohistani N Dapena Diaz JL et al. Inherited biallelic CSF3R mutations in severe congenital neutropenia. Blood (2014) 123(24):3811–7.10.1182/blood-2013-11-53541924753537
23. Kotlarz D Zietara N Uzel G Weidemann T Braun CJ Diestelhorst J et al. Loss-of-function mutations in the IL-21 receptor gene cause a primary immunodeficiency syndrome. J Exp Med (2013) 210(3):433–43.10.1084/jem.2011122923440042
24. Daniels MA Hogquist KA Jameson SC. Sweet ‘n’ sour: the impact of differential glycosylation on T cell responses. Nat Immunol (2002) 3(10):903–10.10.1038/ni1002-90312352967
25. Lau KS Partridge EA Grigorian A Silvescu CI Reinhold VN Demetriou M et al. Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell (2007) 129(1):123–34.10.1016/j.cell.2007.01.04917418791
26. Wolfert MA Boons GJ. Adaptive immune activation: glycosylation does matter. Nat Chem Biol (2013) 9(12):776–84.10.1038/nchembio.140324231619
27. Zhou RW Mkhikian H Grigorian A Hong A Chen D Arakelyan A et al. N-glycosylation bidirectionally extends the boundaries of thymocyte positive selection by decoupling Lck from Ca(2)(+) signaling. Nat Immunol (2014) 15(11):1038–45.10.1038/ni.300725263124
28. Liu SD Whiting CC Tomassian T Pang M Bissel SJ Baum LG et al. Endogenous galectin-1 enforces class I-restricted TCR functional fate decisions in thymocytes. Blood (2008) 112(1):120–30.10.1182/blood-2007-09-11418118323414
29. Moody AM Chui D Reche PA Priatel JJ Marth JD Reinherz EL. Developmentally regulated glycosylation of the CD8alphabeta coreceptor stalk modulates ligand binding. Cell (2001) 107(4):501–12.10.1016/S0092-8674(01)00577-311719190
30. Hayes JM Cosgrave EF Struwe WB Wormald M Davey GP Jefferis R et al. Glycosylation and Fc receptors. Curr Top Microbiol Immunol (2014) 382:165–99.10.1007/978-3-319-07911-0_8
31. Sadat MA Moir S Chun TW Lusso P Kaplan G Wolfe L et al. Glycosylation, hypogammaglobulinemia, and resistance to viral infections. N Engl J Med (2014) 370(17):1615–25.10.1056/NEJMoa130284624716661
32. Ishino T Wang M Mosyak L Tam A Duan W Svenson K et al. Engineering a monomeric Fc domain modality by N-glycosylation for the half-life extension of biotherapeutics. J Biol Chem (2013) 288(23):16529–37.10.1074/jbc.M113.45768923615911
33. Anthony RM Kobayashi T Wermeling F Ravetch JV. Intravenous gammaglobulin suppresses inflammation through a novel T(H)2 pathway. Nature (2011) 475(7354):110–3.10.1038/nature1013421685887
34. Martin CC Oeser JK Svitek CA Hunter SI Hutton JC O’Brien RM. Identification and characterization of a human cDNA and gene encoding a ubiquitously expressed glucose-6-phosphatase catalytic subunit-related protein. J Mol Endocrinol (2002) 29(2):205–22.10.1677/jme.0.029020512370122
35. Belkaid A Copland IB Massillon D Annabi B. Silencing of the human microsomal glucose-6-phosphate translocase induces glioma cell death: potential new anticancer target for curcumin. FEBS Lett (2006) 580(15):3746–52.10.1016/j.febslet.2006.05.07116777101
36. Banka S Chervinsky E Newman WG Crow YJ Yeganeh S Yacobovich J et al. Further delineation of the phenotype of severe congenital neutropenia type 4 due to mutations in G6PC3. Eur J Hum Genet (2011) 19(1):18–22.10.1038/ejhg.2010.13620717171
37. Banka S Newman WG Ozgul RK Dursun A. Mutations in the G6PC3 gene cause Dursun syndrome. Am J Med Genet A (2010) 152A(10):2609–11.10.1002/ajmg.a.3361520799326
38. McDermott DH De Ravin SS Jun HS Liu Q Priel DA Noel P et al. Severe congenital neutropenia resulting from G6PC3 deficiency with increased neutrophil CXCR4 expression and myelokathexis. Blood (2010) 116(15):2793–802.10.1182/blood-2010-01-26594220616219
39. Dursun A Ozgul RK Soydas A Tugrul T Gurgey A Celiker A et al. Familial pulmonary arterial hypertension, leucopenia, and atrial septal defect: a probable new familial syndrome with multisystem involvement. Clin Dysmorphol (2009) 18(1):19–23.10.1097/MCD.0b013e32831841f719011569
40. Boztug K Appaswamy G Ashikov A Schaffer AA Salzer U Diestelhorst J et al. A syndrome with congenital neutropenia and mutations in G6PC3. N Engl J Med (2009) 360(1):32–43.10.1056/NEJMoa080505119118303
41. Boztug K Rosenberg PS Dorda M Banka S Moulton T Curtin J et al. Extended spectrum of human glucose-6-phosphatase catalytic subunit 3 deficiency: novel genotypes and phenotypic variability in severe congenital neutropenia. J Pediatr (2012) 160(4):679–83 e2.10.1016/j.jpeds.2011.09.01922050868
42. Chou JY Jun HS Mansfield BC. Neutropenia in type Ib glycogen storage disease. Curr Opin Hematol (2010) 17(1):36–42.10.1097/MOH.0b013e328331df8519741523
43. Visser G Rake JP Fernandes J Labrune P Leonard JV Moses S et al. Neutropenia, neutrophil dysfunction, and inflammatory bowel disease in glycogen storage disease type Ib: results of the European study on glycogen storage disease type I. J Pediatr (2000) 137(2):187–91.10.1067/mpd.2000.10523210931410
44. Hayee B Antonopoulos A Murphy EJ Rahman FZ Sewell G Smith BN et al. G6PC3 mutations are associated with a major defect of glycosylation: a novel mechanism for neutrophil dysfunction. Glycobiology (2011) 21(7):914–24.10.1093/glycob/cwr02321385794
45. Zhang Y Yu X Ichikawa M Lyons JJ Datta S Lamborn IT et al. Autosomal recessive phosphoglucomutase 3 (PGM3) mutations link glycosylation defects to atopy, immune deficiency, autoimmunity, and neurocognitive impairment. J Allergy Clin Immunol (2014) 133(5):1400–9, 9 e1–5.10.1016/j.jaci.2014.02.013
46. Sassi A Lazaroski S Wu G Haslam SM Fliegauf M Mellouli F et al. Hypomorphic homozygous mutations in phosphoglucomutase 3 (PGM3) impair immunity and increase serum IgE levels. J Allergy Clin Immunol (2014) 133(5):1410–9, 9 e1–13.10.1016/j.jaci.2014.02.02524698316
47. Stray-Pedersen A Backe PH Sorte HS Morkrid L Chokshi NY Erichsen HC et al. PGM3 mutations cause a congenital disorder of glycosylation with severe immunodeficiency and skeletal dysplasia. Am J Hum Genet (2014) 95(1):96–107.10.1016/j.ajhg.2014.05.00724931394
48. Greig KT Antonchuk J Metcalf D Morgan PO Krebs DL Zhang JG et al. Agm1/Pgm3-mediated sugar nucleotide synthesis is essential for hematopoiesis and development. Mol Cell Biol (2007) 27(16):5849–59.10.1128/MCB.00802-0717548465
49. Grunewald S. The clinical spectrum of phosphomannomutase 2 deficiency (CDG-Ia). Biochim Biophys Acta (2009) 1792(9):827–34.10.1016/j.bbadis.2009.01.00319272306
50. Blank C Smith LA Hammer DA Fehrenbach M Delisser HM Perez E et al. Recurrent infections and immunological dysfunction in congenital disorder of glycosylation Ia (CDG Ia). J Inherit Metab Dis (2006) 29(4):592.10.1007/s10545-006-0275-216826448
51. Grubenmann CE Frank CG Hulsmeier AJ Schollen E Matthijs G Mayatepek E et al. Deficiency of the first mannosylation step in the N-glycosylation pathway causes congenital disorder of glycosylation type Ik. Hum Mol Genet (2004) 13(5):535–42.10.1093/hmg/ddh05014709599
52. Kranz C Denecke J Lehle L Sohlbach K Jeske S Meinhardt F et al. Congenital disorder of glycosylation type Ik (CDG-Ik): a defect of mannosyltransferase I. Am J Hum Genet (2004) 74(3):545–51.10.1086/38249314973782
53. Schwarz M Thiel C Lubbehusen J Dorland B de Koning T von Figura K et al. Deficiency of GDP-Man:GlcNAc2-PP-dolichol mannosyltransferase causes congenital disorder of glycosylation type Ik. Am J Hum Genet (2004) 74(3):472–81.10.1086/382492
54. Dupre T Vuillaumier-Barrot S Chantret I Yaye HS Le Bizec C Afenjar A et al. Guanosine diphosphate-mannose:GlcNAc2-PP-dolichol mannosyltransferase deficiency (congenital disorders of glycosylation type Ik): five new patients and seven novel mutations. J Med Genet (2010) 47(11):729–35.10.1136/jmg.2009.07250420679665
55. Kranz C Basinger AA Gucsavas-Calikoglu M Sun L Powell CM Henderson FW et al. Expanding spectrum of congenital disorder of glycosylation Ig (CDG-Ig): sibs with a unique skeletal dysplasia, hypogammaglobulinemia, cardiomyopathy, genital malformations, and early lethality. Am J Med Genet A (2007) 143A(12):1371–8.10.1002/ajmg.a.3179117506107
56. De Praeter CM Gerwig GJ Bause E Nuytinck LK Vliegenthart JF Breuer W et al. A novel disorder caused by defective biosynthesis of N-linked oligosaccharides due to glucosidase I deficiency. Am J Hum Genet (2000) 66(6):1744–56.10.1086/30294810788335
57. Martinez-Duncker I Dupre T Piller V Piller F Candelier JJ Trichet C et al. Genetic complementation reveals a novel human congenital disorder of glycosylation of type II, due to inactivation of the Golgi CMP-sialic acid transporter. Blood (2005) 105(7):2671–6.10.1182/blood-2004-09-350915576474
58. Boztug K Jarvinen PM Salzer E Racek T Monch S Garncarz W et al. JAGN1 deficiency causes aberrant myeloid cell homeostasis and congenital neutropenia. Nat Genet (2014) 46(9):1021–7.10.1038/ng.306925129144
59. Wirnsberger G Zwolanek F Stadlmann J Tortola L Liu SW Perlot T et al. Jagunal homolog 1 is a critical regulator of neutrophil function in fungal host defense. Nat Genet (2014) 46(9):1028–33.10.1038/ng.307025129145
60. Marquardt T Luhn K Srikrishna G Freeze HH Harms E Vestweber D. Correction of leukocyte adhesion deficiency type II with oral fucose. Blood (1999) 94(12):3976–85.10590041
61. Etzioni A Tonetti M. Fucose supplementation in leukocyte adhesion deficiency type II. Blood (2000) 95(11):3641–3.
62. Luhn K Marquardt T Harms E Vestweber D. Discontinuation of fucose therapy in LADII causes rapid loss of selectin ligands and rise of leukocyte counts. Blood (2001) 97(1):330–2.10.1182/blood.V97.1.33011133780
63. Hidalgo A Ma S Peired AJ Weiss LA Cunningham-Rundles C Frenette PS. Insights into leukocyte adhesion deficiency type 2 from a novel mutation in the GDP-fucose transporter gene. Blood (2003) 101(5):1705–12.10.1182/blood-2002-09-284012406889
64. Niehues R Hasilik M Alton G Korner C Schiebe-Sukumar M Koch HG et al. Carbohydrate-deficient glycoprotein syndrome type Ib. Phosphomannose isomerase deficiency and mannose therapy. J Clin Invest (1998) 101(7):1414–20.10.1172/JCI23509525984
65. Harms HK Zimmer KP Kurnik K Bertele-Harms RM Weidinger S Reiter K. Oral mannose therapy persistently corrects the severe clinical symptoms and biochemical abnormalities of phosphomannose isomerase deficiency. Acta Paediatr (2002) 91(10):1065–72.10.1111/j.1651-2227.2002.tb00101.x12434892
66. Kjaergaard S Kristiansson B Stibler H Freeze HH Schwartz M Martinsson T et al. Failure of short-term mannose therapy of patients with carbohydrate-deficient glycoprotein syndrome type 1A. Acta Paediatr (1998) 87(8):884–8.10.1111/j.1651-2227.1998.tb01556.x9736238
67. Tegtmeyer LC Rust S van Scherpenzeel M Ng BG Losfeld ME Timal S et al. Multiple phenotypes in phosphoglucomutase 1 deficiency. N Engl J Med (2014) 370(6):533–42.10.1056/NEJMoa120660524499211
68. Chu VC Whittaker GR. Influenza virus entry and infection require host cell N-linked glycoprotein. Proc Natl Acad Sci U S A (2004) 101(52):18153–8.10.1073/pnas.040517210215601777
69. Geijtenbeek TB Kwon DS Torensma R van Vliet SJ van Duijnhoven GC Middel J et al. DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell (2000) 100(5):587–97.10.1016/S0092-8674(00)80694-710721995
70. Ahmed SP Nash RJ Bridges CG Taylor DL Kang MS Porter EA et al. Antiviral activity and metabolism of the castanospermine derivative MDL 28,574, in cells infected with herpes simplex virus type 2. Biochem Biophys Res Commun (1995) 208(1):267–73.10.1006/bbrc.1995.13337887939
71. Fischer PB Karlsson GB Dwek RA Platt FM. N-butyldeoxynojirimycin-mediated inhibition of human immunodeficiency virus entry correlates with impaired gp120 shedding and gp41 exposure. J Virol (1996) 70(10):7153–60.8794362
72. Qu X Pan X Weidner J Yu W Alonzi D Xu X et al. Inhibitors of endoplasmic reticulum alpha-glucosidases potently suppress hepatitis C virus virion assembly and release. Antimicrob Agents Chemother (2011) 55(3):1036–44.10.1128/AAC.01319-1021173177
73. Fischl MA Resnick L Coombs R Kremer AB Pottage JC Jr Fass RJ et al. The safety and efficacy of combination N-butyl-deoxynojirimycin (SC-48334) and zidovudine in patients with HIV-1 infection and 200-500 CD4 cells/mm3. J Acquir Immune Defic Syndr (1994) 7(2):139–47.7905523
74. Gantt S Gachelet E Carlsson J Barcy S Casper C Lagunoff M. Nelfinavir impairs glycosylation of herpes simplex virus 1 envelope proteins and blocks virus maturation. Adv Virol (2015) 2015:687162.10.1155/2015/68716225709648
75. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc Natl Acad Sci U S A (2002) 99(16):10231–3.10.1073/pnas.172380699
76. Mkhikian H Grigorian A Li CF Chen HL Newton B Zhou RW et al. Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis. Nat Commun (2011) 2:334.10.1038/ncomms133321629267
77. Guevara J Espinosa B Zenteno E Vazguez L Luna J Perry G et al. Altered glycosylation pattern of proteins in Alzheimer disease. J Neuropathol Exp Neurol (1998) 57(10):905–14.10.1097/00005072-199810000-000039786241
78. Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood (2014) 124(18):2804–11.10.1182/blood-2014-02-52212825237200
79. Malhotra R Wormald MR Rudd PM Fischer PB Dwek RA Sim RB. Glycosylation changes of IgG associated with rheumatoid arthritis can activate complement via the mannose-binding protein. Nat Med (1995) 1(3):237–43.10.1038/nm0395-2377585040
80. Coppo R Amore A. Aberrant glycosylation in IgA nephropathy (IgAN). Kidney Int (2004) 65(5):1544–7.10.1111/j.1523-1755.2004.05407.x15086888
81. Janssen MJ Waanders E Woudenberg J Lefeber DJ Drenth JP. Congenital disorders of glycosylation in hepatology: the example of polycystic liver disease. J Hepatol (2010) 52(3):432–40.10.1016/j.jhep.2009.12.01120138683